Table2: Frequency of adverse events in both treatment phases; intensive and continuation phases respectively

Grouped adverse events	Specific adverse events	Both phases (N=53)*	%	Intensive phase (N=53)	%	Continuation phase (N=49)†	%
Hearing loss & Tinnitus	Tinnitus	24	45%	21	40%	3	6%
	Decreased hearing	13	25%	12	23%	1	2%
	Hearing loss & Tinnitus Total	37	70%	33	62%	4	8%
GIT-related	Nausea	12	23%	8	15%	4	8%
	Abdominal pain	9	17%	8	15%	1	2%
	Vomiting	6	11%	6	11%	0	0%
	Diarrhea	5	9%	5	9%	0	0%
	Constipation	2	4%	2	4%	0	0%
	GIT Total	34	64%	29	55%	5	10%
Others	Joint pain	15	28%	13	25%	2	4%
	Headache	11	21%	10	19%	1	2%
	Fatigue	10	19%	8	15%	2	4%
	Dizziness	8	15%	7	13%	1	2%
	Rash	7	13%	7	13%	0	0%
	Neuropathy	4	8%	2	4%	2	4%
	Fever	3	6%	3	6%	0	0%
	Vision changes	3	6%	2	4%	1	2%
	Depression	2	4%	2	4%	0	0%
	Psychosis	2	4%	2	4%	0	0%
	Severe hepatitis	1	2%	1	2%	0	0%
	Decreased urine	1	2%	1	2%	0	0%
	Anemia	2	4%	2	4%	0	0%
	Loss of libido, delayed ejaculation	1	2%	0	0%	1	2%
Total of all adverse events		141		122		19
Percent of all adverse events		100%		87%		13%

^* 53 of the 59 patients reported to have experienced at least one DR-TB treatment-related adverse event. All the 53 patients had either completed or were still in the intensive phase of treatment at the time of data collection.

^† 49 of the patients had progressed into the continuation phase of treatment and were either still on continuation phase treatment or had completed treatment at the time of data collection.

%= percent. Sum of column percentages may exceed 100% because a patient may experience more than one adverse event. GIT = gastrointestinal tract